European Journal of Clinical Pharmacology

, Volume 74, Issue 10, pp 1261–1272 | Cite as

Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects

  • Eunwoo Kim
  • Anhye Kim
  • Sojeong Yi
  • Yu Kyong Kim
  • Seong Bok Jang
  • Hae Mi Byun
  • Seo Hyun Yoon
  • Joo-Youn Cho
  • In-Jin Jang
  • Kyung-Sang Yu
  • SeungHwan LeeEmail author
Clinical Trial



YH4808 is a potassium-competitive acid blocker, developed for the treatment of acid-related disorders. Two clinical studies in healthy male subjects were conducted to evaluate the effect of food on the pharmacokinetics of YH4808.


The first study, a randomized, three-treatment, three-period, crossover study, compared pharmacokinetics of YH4808 (300 mg) after a single dose at fed state with a standard or a high-fat meal to those at fasted state. The second study, a randomized, two-treatment, two-period, crossover study, investigated pharmacokinetics at fasted or fed state with a standard meal after twice daily dose of YH4808 (100 mg) for 7 days. Bloods for pharmacokinetic evaluation were sampled up to 48 h post-dose and 24 h post-dose at steady state, respectively. The pharmacokinetic parameters were estimated by non-compartmental method.


After single dosing, the geometric means of maximum plasma concentration increased by 1.2 and 2.1 times in the fed states with a standard meal and a high-fat meal, respectively, of that in fasted state. Corresponding values of area under the plasma concentration-time curve (AUC) from time 0 to the last measurable time point increased by 1.8 and 2.8 times, respectively. After multiple dosing, the geometric mean for 24-h AUC at steady state slightly increased in fed state by 1.1 times of that in fasted state.


As fat content of the food increased, the systemic exposure of YH4808 after single dosing increased. However, systemic exposures at steady state after multiple dosing between fasted and fed states were similar.

Trial registration registry no.: NCT01520012


YH4808 Potassium competitive acid blocker Pharmacokinetics Food effect 


Funding information

This study was funded by Yuhan Co. Ltd., Seoul, Republic of Korea.

Compliance with ethical standards

The protocol was approved by the institutional review board of Seoul National University Hospital (SNUH). The studies were conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization guidelines. Written informed consents were obtained prior to enrolment in the studies.

Conflict of interest

The authors Seong Bok Jang and Hae Mi Byun are employees of Yuhan Co. Ltd. The first author (Eunwoo Kim) received a scholarship from the BK21-plus education program provided by the National Research Foundation of Korea. Sojeong Yi is currently employed by the U.S. Food and Drug Administration. Her contribution to the manuscript was based on her prior employment, and the current manuscript does not reflect any position of neither the U.S. Food and Drug Administration nor the US government. The authors have no other potential conflicts of interest to disclose regarding the content of this article.


  1. 1.
    Katz PO (1998) Gastroesophageal reflux disease. J Am Geriatr Soc 46(12):1558–1565CrossRefPubMedGoogle Scholar
  2. 2.
    Maradey-Romero C, Fass R (2014) New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 20(1):6–16CrossRefPubMedGoogle Scholar
  3. 3.
    Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, Takagi A, Chiba T, Nomura S, Mizokami Y, Murakami K, Sakamoto C, Hiraishi H, Ichinose M, Uemura N, Goto H, Joh T, Miwa H, Sugano K, Shimosegawa T (2016) Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol 51(3):177–194CrossRefPubMedGoogle Scholar
  4. 4.
    Malfertheiner P, Chan FK, McColl KE (2009) Peptic ulcer disease. Lancet 374(9699):1449–1461CrossRefPubMedGoogle Scholar
  5. 5.
    Sachs G (2001) Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 13(Suppl 1):S35–S41PubMedGoogle Scholar
  6. 6.
    Katz PO, Hatlebakk JG, Castell DO (2000) Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 14(6):709–714CrossRefPubMedGoogle Scholar
  7. 7.
    Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20(3):153–167CrossRefPubMedGoogle Scholar
  8. 8.
    Hunt RH, Scarpignato C (2015) Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol 6:e119CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Andersson K, Carlsson E (2005) Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 108(3):294–307CrossRefPubMedGoogle Scholar
  10. 10.
    Echizen H (2016) The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 55(4):409–418CrossRefPubMedGoogle Scholar
  11. 11.
    Yuhan Co. Ltd. S. YH4808 Investigator Brochure (Ver 11.0). 2013. UnpublishedGoogle Scholar
  12. 12.
    Yi S, Lee H, Jang SB, Byun HM, Yoon SH, Cho JY, Jang IJ, Yu KS (2017) A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers. Aliment Pharmacol Ther 46:337–346CrossRefPubMedGoogle Scholar
  13. 13.
    KIST (Korea Institute of Science and Technology). ADME study of YH4808 using isotope (Yuhan Co. Ltd., Seoul). 2008. UnpublishedGoogle Scholar
  14. 14.
    Charman WN, Porter CJH, Mithani S, Dressman JB (1997) Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86(3):269–282CrossRefPubMedGoogle Scholar
  15. 15.
    U.S. Department of Health and Human Services. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence Studies 2002Google Scholar
  16. 16.
    Rowland M, Tozer TN (2010) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 184Google Scholar
  17. 17.
    Welling PG (1996) Effects of food on drug absorption. Annu Rev Nutr 16:383–415CrossRefPubMedGoogle Scholar
  18. 18.
    Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57(2):218–222CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lee PID, Amidon GL (1996) Pharmacokinetic analysis: a practical approach. CRC Press, Boca Raton, p 324Google Scholar
  20. 20.
    Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37(3):213–255CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Eunwoo Kim
    • 1
  • Anhye Kim
    • 2
  • Sojeong Yi
    • 1
  • Yu Kyong Kim
    • 1
  • Seong Bok Jang
    • 3
  • Hae Mi Byun
    • 3
  • Seo Hyun Yoon
    • 1
  • Joo-Youn Cho
    • 1
  • In-Jin Jang
    • 1
  • Kyung-Sang Yu
    • 1
  • SeungHwan Lee
    • 1
    • 4
    Email author
  1. 1.Department of Clinical Pharmacology and TherapeuticsSeoul National University College of Medicine and HospitalSeoulRepublic of Korea
  2. 2.Clinical Trial CenterAjou University Medical CenterSuwonRepublic of Korea
  3. 3.Clinical Development TeamYuhan Co. Ltd.SeoulRepublic of Korea
  4. 4.Clinical Trials CenterSeoul National University HospitalSeoulRepublic of Korea

Personalised recommendations